NEWS
$10 million invested in AI disease detection
Leidos is committing $10 million to accelerate the use of artificial intelligence for detecting and managing diseases, in collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE). The initial focus of the five-year collaboration will be developing AI- powered tools for quicker detection of diseases, such as heart disease and cancer, reducing diagnostic turnaround times, and enabling earlier, more effective care management.
“Our investment is aimed at using the transformative power of artificial intelligence to speed detection, diagnosis and treatment of diseases that affect millions of people annually,” said Leidos CEO Tom Bell. “These efforts will also focus on developing future health care specialists.” For more than 25 years, Leidos has operated the National Cancer Institute’s Frederick National Laboratory for Cancer Research, supporting progress in the fight against cancer. The company also brings more than two decades of experience applying AI to important areas like health care, national security, and energy, and helps improve care for military families and veterans by strengthening delivery, access, and continuity of care. Through this multi-year collaboration, Leidos and the University of Pittsburgh will drive advances in research and technology development as well as workforce development and education.
Advanced Instruments to acquire Nova Biomedical
Advanced Instruments has announced a definitive agreement to acquire fellow biotechnology company Nova Biomedical.
Following the closing of the transaction, Advanced Instruments (a subsidiary of Patricia Industries) and Nova Biomedical will merge, creating a global life science tools platform that will operate under the Nova Biomedical name, with a diversified portfolio of analytical instruments, reagents and services. Byron Selman, President & CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical founding shareholders Frank Manganaro, CEO and Dr Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity.
“Combining these two great companies aligns with our core strategy to develop and commercialise best-in-class technologies that deliver significant customer value across the biopharma and clinical markets,” commented Mr Selman. “The combination of our technologies, R&D strength, global sales network, dedicated teams and commitment to innovation will advance our collective ability to support customer workflows within various stages of drug development and bioprocessing and expand our footprint within the hospital and
other healthcare settings, guiding patient care with our diversified product portfolio and supporting our growing customer base.” “We are excited to unite with the Advanced Instruments team,” said Frank Manganaro. “Our companies share similar values and objectives including a vision for sustained innovation, a strong commitment to the end markets we respectively serve and above all a strong connection to improving patient care globally. Bringing together our strong teams, focus on innovation and dedication to the customer will strengthen our combined companies and support a bright future for Nova Biomedical.”
Closing is subject to regulatory approval and is expected during the third quarter of 2025.
RDi completes strategic acquisition of Inicio Health
LDC-backed RDi, a leader in data driven, automated self-sampling kits for healthcare, has announced the successful acquisition of Inicio Health, a pioneering force in healthcare interoperability, automation and AI solutions.
The acquisition unites two forward- thinking companies with a shared mission of delivering smarter, more accessible people-centric pathways for screening, diagnostics, and preventative healthcare. By combining RDi’s expertise in self-sampling and testing kits with Inicio Health’s cutting-edge digital interoperability and transformation
12
solutions, the partnership will drive significant advancements in the way people access and engage with healthcare. Patients will benefit from seamless digital experiences, increased accessibility, and more efficient diagnostics all with the convenience of self-testing at home. Together, the two companies will accelerate the development of advanced digital solutions which empower individuals to take control of their health, while also enabling healthcare providers to deliver more efficient and scalable care. This acquisition, RDi’s third since LDC’s investment in September 2021, represents
a major step forward in the evolution of end-to-end self-sampling pathways in healthcare, ensuring that both companies’ combined expertise will continue to push boundaries in screening, diagnostics, and remote patient care.
RDi is a UK-based healthcare and medical devices company specialising in data-driven, automated solutions including fulfilment services for diagnostics and medical kitting. Established in 2004, RDi has become a leader in delivering highly personalised and scalable solutions for healthcare providers including the NHS.
MAY 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
